Dr. Reddy's Laboratories has recently introduced a groundbreaking cancer drug called Toripalimab in India. This drug is a major breakthrough in the treatment of a rare form of neck cancer known as nasopharyngeal carcinoma.

Toripalimab is the first and only immuno-oncology treatment that has been approved for this particular condition. Dr. Reddy's entered into a licensing and commercialization agreement with Shanghai Junshi Biosciences in 2023, granting them exclusive rights to develop and market Toripalimab in 21 countries, including India, South Africa, and Brazil.

With this launch, India becomes the third country, after China and the United States, to have access to Toripalimab, which will be sold under the brand name Zytorvi. M.V. Ramana, CEO of Branded Markets at Dr. Reddy's, emphasized the significance of this launch for patients with advanced stages of nasopharyngeal carcinoma, highlighting the high disease burden in India.